154 related articles for article (PubMed ID: 37108234)
1. In Vitro and In Vivo Effects of the Combination of Polypurine Reverse Hoogsteen Hairpins against HER-2 and Trastuzumab in Breast Cancer Cells.
López-Aguilar E; Fernández-Nogueira P; Fuster G; Carbó N; Ciudad CJ; Noé V
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108234
[TBL] [Abstract][Full Text] [Related]
2. Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo.
Rodríguez L; Villalobos X; Dakhel S; Padilla L; Hervas R; Hernández JL; Ciudad CJ; Noé V
Biochem Pharmacol; 2013 Dec; 86(11):1541-54. PubMed ID: 24070653
[TBL] [Abstract][Full Text] [Related]
3. Effect of Polypurine Reverse Hoogsteen Hairpins on Relevant Cancer Target Genes in Different Human Cell Lines.
Villalobos X; Rodríguez L; Solé A; Lliberós C; Mencia N; Ciudad CJ; Noé V
Nucleic Acid Ther; 2015 Aug; 25(4):198-208. PubMed ID: 26042602
[TBL] [Abstract][Full Text] [Related]
4. Coding polypurine hairpins cause target-induced cell death in breast cancer cells.
de Almagro MC; Mencia N; Noé V; Ciudad CJ
Hum Gene Ther; 2011 Apr; 22(4):451-63. PubMed ID: 20942657
[TBL] [Abstract][Full Text] [Related]
5. Polypurine Reverse Hoogsteen Hairpins as a Gene Silencing Tool for Cancer.
Ciudad CJ; Rodríguez L; Villalobos X; Félix AJ; Noé V
Curr Med Chem; 2017; 24(26):2809-2826. PubMed ID: 28260512
[TBL] [Abstract][Full Text] [Related]
6. Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells.
Aubets E; Noé V; Ciudad CJ
Biochem Pharmacol; 2020 May; 175():113911. PubMed ID: 32173365
[TBL] [Abstract][Full Text] [Related]
7. PolyPurine Reverse Hoogsteen Hairpins Work as RNA Species for Gene Silencing.
Aubets E; Chillon M; Ciudad CJ; Noé V
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576188
[TBL] [Abstract][Full Text] [Related]
8. Improved design of PPRHs for gene silencing.
Rodríguez L; Villalobos X; Solé A; Lliberós C; Ciudad CJ; Noé V
Mol Pharm; 2015 Mar; 12(3):867-77. PubMed ID: 25615267
[TBL] [Abstract][Full Text] [Related]
9. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Noé V; Aubets E; Félix AJ; Ciudad CJ
Biochem Pharmacol; 2021 Jul; 189():114371. PubMed ID: 33338475
[TBL] [Abstract][Full Text] [Related]
10. Silencing of CD47 and SIRPα by Polypurine reverse Hoogsteen hairpins to promote MCF-7 breast cancer cells death by PMA-differentiated THP-1 cells.
Bener G; J Félix A; Sánchez de Diego C; Pascual Fabregat I; Ciudad CJ; Noé V
BMC Immunol; 2016 Sep; 17(1):32. PubMed ID: 27671753
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.
Medina Enríquez MM; Félix AJ; Ciudad CJ; Noé V
PLoS One; 2018; 13(11):e0206818. PubMed ID: 30399174
[TBL] [Abstract][Full Text] [Related]
12. Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes.
de Almagro MC; Coma S; Noé V; Ciudad CJ
J Biol Chem; 2009 Apr; 284(17):11579-89. PubMed ID: 19261618
[TBL] [Abstract][Full Text] [Related]
13. Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins.
Villalobos X; Rodríguez L; Prévot J; Oleaga C; Ciudad CJ; Noé V
Mol Pharm; 2014 Jan; 11(1):254-64. PubMed ID: 24251728
[TBL] [Abstract][Full Text] [Related]
14. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
[TBL] [Abstract][Full Text] [Related]
15. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
16. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
[TBL] [Abstract][Full Text] [Related]
17. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
18. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
Belkhiri A; Dar AA; Peng DF; Razvi MH; Rinehart C; Arteaga CL; El-Rifai W
Clin Cancer Res; 2008 Jul; 14(14):4564-71. PubMed ID: 18579663
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
